Reading view

New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

© Mike Blake/Reuters

Eli Lilly company offices in San Diego. The company reported results of retatrutide, its next-generation weight-loss drug.
  •  

12 former FDA chiefs unite to say agency memo on vaccines is deeply stupid

On Friday, Vinay Prasad—the Food and Drug Administration’s chief medical and scientific officer and its top vaccine regulator—emailed a stunning memo to staff that quickly leaked to the press. Without evidence, Prasad claimed COVID-19 vaccines have killed 10 children in the US, and, as such, he announced unilateral, sweeping changes to the way the agency regulates and approves vaccines, including seasonal flu shots.

On Wednesday evening, a dozen former FDA commissioners, who collectively oversaw the agency for more than 35 years, responded to the memo with a scathing rebuke. Uniting to publish their response in the New England Journal of Medicine, the former commissioners said they were “deeply concerned” by Prasad’s memo, which they framed as a “threat” to the FDA’s work and a danger to Americans’ health.

In his memo, Prasad called for abandoning the FDA’s current framework for updating seasonal flu shots and other vaccines, such as those for COVID-19. Those updates currently involve studies that measure well-characterized immune responses (called immunobridging studies). Prasad dismissed this approach as insufficient and, instead, plans to require expensive randomized trials, which can take months to years for each vaccine update.

Read full article

Comments

© Getty | Joe Raedle

  •  

GLP-1 Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.

© Hollie Adams/Reuters

A trial of semaglutide, the miracle drug branded as Ozempic and Wegovy for diabetes and weight loss, failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or dementia.
  •  

Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease risk.

© Andrew Kelly/Reuters

Merck, which first introduced statins to the world nearly 40 years ago, announced that its new pill helped reduce heart attack and stroke rates in high risk patients by 20 percent in a year.
  •